Barclays PLC Immunome Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Immunome Inc. stock. As of the latest transaction made, Barclays PLC holds 28,994 shares of IMNM stock, worth $433,170. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,994
Previous 82,455
64.84%
Holding current value
$433,170
Previous $882,000
18.93%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding IMNM
# of Institutions
106Shares Held
32.1MCall Options Held
46.1KPut Options Held
32.5K-
Redmile Group, LLC San Francisco, CA4.89MShares$73 Million4.76% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.88MShares$58 Million2.73% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.25MShares$33.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.02MShares$30.2 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.64MShares$24.5 Million0.1% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $181M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...